Paper · 28126304
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 37
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17000658 | The epidermal growth factor receptor pathway: a model for targeted therapy. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/17000658 | PubMed |
| 2 | 15578079 | Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. | Mod Pathol | 2005 | https://conductscience.org/library/papers/15578079 | PubMed |
| 3 | 8874455 | Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. | Lancet | 1996 | https://conductscience.org/library/papers/8874455 | PubMed |
| 4 | 10888772 | Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. | Arch Pathol Lab Med | 2000 | https://conductscience.org/library/papers/10888772 | PubMed |
| 5 | 24662454 | Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24662454 | PubMed |
| 6 | 18430910 | Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. | JAMA | 2008 | https://conductscience.org/library/papers/18430910 | PubMed |
| 7 | 24127500 | The increasing incidence of anal cancer: can it be explained by trends in risk groups? | Neth J Med | 2013 | https://conductscience.org/library/papers/24127500 | PubMed |
| 8 | 27052656 | Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27052656 | PubMed |
| 9 | 24035327 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/24035327 | PubMed |
| 10 | 24642661 | KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). | PLoS One | 2014 | https://conductscience.org/library/papers/24642661 | PubMed |
| 11 | 24595598 | EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. | J Cancer Res Clin Oncol | 2014 | https://conductscience.org/library/papers/24595598 | PubMed |
| 12 | 25042878 | EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. | Radiother Oncol | 2014 | https://conductscience.org/library/papers/25042878 | PubMed |
| 13 | 20152769 | Ki67 in breast cancer: prognostic and predictive potential. | Lancet Oncol | 2010 | https://conductscience.org/library/papers/20152769 | PubMed |
| 14 | 23150707 | Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/23150707 | PubMed |
| 15 | 24021343 | p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. | Radiother Oncol | 2013 | https://conductscience.org/library/papers/24021343 | PubMed |
| 16 | 12389040 | Automated subcellular localization and quantification of protein expression in tissue microarrays. | Nat Med | 2002 | https://conductscience.org/library/papers/12389040 | PubMed |
| 17 | 19923868 | Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. | Oncology | 2009 | https://conductscience.org/library/papers/19923868 | PubMed |
| 18 | 22949905 | Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer. | Case Rep Oncol | 2012 | https://conductscience.org/library/papers/22949905 | PubMed |
| 19 | 23755922 | Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/23755922 | PubMed |
| 20 | 1683905 | A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. | J Pathol | 1991 | https://conductscience.org/library/papers/1683905 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/28126304/references